<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03619044</url>
  </required_header>
  <id_info>
    <org_study_id>18 SEIN 08</org_study_id>
    <nct_id>NCT03619044</nct_id>
  </id_info>
  <brief_title>The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.</brief_title>
  <acronym>REVER</acronym>
  <official_title>The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, prospective and multicentric study aiming to highlight by FES-PET&#xD;
      imaging that an anti-HER2 treatment by trastuzumab + pertuzumab can reverse the ERα status in&#xD;
      patients with metastatic breast cancer HER2 + and ERα neg.&#xD;
&#xD;
      For each included patient, 2 FES-PET Imaging will be performed for the study (before cancer&#xD;
      treatment initiation and before the cycle 3 of treatment) at the IUCT-O center (Institut&#xD;
      Universitaire du Cancer de Toulouse).&#xD;
&#xD;
      Treatment (trastuzumab + pertuzumab + taxane) will be administered according to the current&#xD;
      recommendations in each participant center.&#xD;
&#xD;
      Patients will be followed during the 3 cycles of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients with conversion of FES negative lesions in FES positive lesions.</measure>
    <time_frame>Cycle 3 Day 1 for each patient.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of patients with FES positive lesions before treatment.</measure>
    <time_frame>Cycle 4 Day 1 for each patient.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adverse events due to FES-PET imaging evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.</measure>
    <time_frame>Cycle 4 Day 1 for each patient.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with metastatic breast cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 FES-PET Imaging will be performed:</intervention_name>
    <description>before treatment initiation&#xD;
before treatment cycle 3 initiation</description>
    <arm_group_label>Patients with metastatic breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Patient with metastatic breast cancer HER2 + (IHC+++ and/or HER2 amplification in ISH&#xD;
             according to ASCO recommendations), ERα neg (0% in IHC) and Progesterone Receptor neg&#xD;
             (0% in IHC).&#xD;
&#xD;
          3. Patient eligible according to the investigator for a treatment with trastuzumab +&#xD;
             pertuzumab + taxane in the metastatic first line.&#xD;
&#xD;
          4. Available biopsy of a tumor lesion (archived material) or biopsiable tumor lesion for&#xD;
             study (primitive tumor or metastasis other than bone).&#xD;
&#xD;
          5. OMS ≤ 2.&#xD;
&#xD;
          6. For non-menopausal patients, use of an effective contraceptive method at entry into&#xD;
             the study and for the duration of the study.&#xD;
&#xD;
          7. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
          8. Patient must provide written informed consent prior to any study specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous treatment for metastatic disease.&#xD;
&#xD;
          2. Prior adjuvant treatment with anti-HER2 antibodies taken within 6 months.&#xD;
&#xD;
          3. Patient with isolated hepatic metastasis.&#xD;
&#xD;
          4. Patient with hemostasis disorders.&#xD;
&#xD;
          5. Unbalanced Diabetes.&#xD;
&#xD;
          6. Patient with usual formal contraindication to PET/TDM Imaging.&#xD;
&#xD;
          7. Patient who has already started trastuzumab + pertuzumab + taxane treatment.&#xD;
&#xD;
          8. Pregnant or breastfeeding women.&#xD;
&#xD;
          9. Any psychological, familial, geographical or sociological condition which does not&#xD;
             allow to respect the medical follow-up and/or compliance to study procedure.&#xD;
&#xD;
         10. Patient protected by law.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florence DALENC, MD-PhD</last_name>
    <phone>5 31 15 51 04</phone>
    <email>dalenc.florence@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédéric COURBON, MD-PhD</last_name>
    <phone>05 31 15 56 27</phone>
    <email>courbon.frederic@iuct-oncopole.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann BERGE, MD</last_name>
      <phone>05 63 77 77 57</phone>
      <email>berge@claude-bernard-albi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Auch</name>
      <address>
        <city>Auch</city>
        <zip>32008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine SALIGNON, MD</last_name>
      <phone>05 62 61 94 65</phone>
      <email>K.SALIGNON@ch-auch.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Capio La Croix Du Sud</name>
      <address>
        <city>Quint-fonsegrives</city>
        <zip>31130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kheloudja BOUYOUCEF, MD</last_name>
      <phone>05 32 02 72 44</phone>
      <email>k.bouyoucef@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Rodez</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique FABRE, MD</last_name>
      <phone>05 65 55 12 12</phone>
      <email>VE.FABRE@ch-rodez.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT-O</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DALENC, MD-PhD</last_name>
      <phone>05 31 15 51 22</phone>
      <email>dalenc.florence@iuct-oncopole.fr</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric COURBON, MD-PhD</last_name>
      <phone>05 31 15 56 27</phone>
      <email>Courbon.Frederic@iuct-oncopole.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal BERNARD-MARTY, MD</last_name>
      <phone>05 67 20 44 01</phone>
      <email>cbernardm@clinique-pasteur.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>FES-PET</keyword>
  <keyword>HER2-positive Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

